Montrouge, France

Sophie Hallakou-Bozec

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 33(Granted Patents)


Location History:

  • Montrouge, FR (2012 - 2016)
  • Antony, FR (2016 - 2023)

Company Filing History:


Years Active: 2012-2023

Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Sophie Hallakou-Bozec

Introduction

Sophie Hallakou-Bozec is a prominent inventor based in Montrouge, France. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of genetic neurodegenerative diseases and heart failure. With a total of 14 patents to her name, her work has garnered attention in the scientific community.

Latest Patents

Among her latest patents is the invention related to the use of a thienopyridone derivative in the treatment of adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN). This invention focuses on a pharmaceutical composition that utilizes this derivative to address these genetic conditions. Additionally, she has developed methods for treating heart failure with preserved ejection fraction (HFPEF), which involves administering imeglimin to patients at risk of this condition.

Career Highlights

Sophie has worked with notable companies such as Poxel and Merck Patent GmbH, where she has applied her expertise in drug development and innovation. Her career reflects a commitment to advancing medical treatments and improving patient outcomes through her inventions.

Collaborations

Throughout her career, Sophie has collaborated with esteemed colleagues, including Daniel Cravo and Franck F Lepifre. These partnerships have contributed to her success and the impact of her work in the pharmaceutical industry.

Conclusion

Sophie Hallakou-Bozec's innovative contributions to the field of medicine highlight her dedication to addressing critical health issues. Her patents and collaborations demonstrate her significant role in advancing pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…